Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

US Patent 9453220 · Granted Sep 27, 2016

Estimated economic value: $3,576,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Back interface for rack shelf2025
Method for treating pruritus2025
Fixation members, assemblies, and related systems and methods2023
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-relat2017
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-relat2017
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-relat2017
RNAi-mediated inhibition of histamine receptor H1-related conditions2017
RNAi-mediated inhibition of histamine receptor H1-related conditions2017
RNAi-mediated inhibition of histamine receptor H1-related conditions2017
High concentration olopatadine ophthalmic composition2017
RNAi-mediated inhibition of tumor necrosis factor α-related conditions2016
RNAi-mediated inhibition of tumor necrosis factor α-related conditions2016